Azitra, Inc. (AZTR) stock
AZTRNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.61−0.06 (-8.99%)
Close on Nov 13, 2026Market cap $3.69MP/E –Yield –
Azitra r&d expenses
Research and development expenses are spending on new products and technology.
Azitra's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.21M, up 5.2% year over year. For fiscal 2025 it was $4.84M, up 2.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.84M | +2.4% |
| FY2024 | Dec 31, 2024 | $4.72M | +29.6% |
| FY2023 | Dec 31, 2023 | $3.64M | -40.3% |
| FY2022 | Dec 31, 2022 | $6.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.29M | +9.4% |
| Q2 FY2026 | Jun 30, 2026 | $1.35M | -3.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.56M | +24.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.00M | -10.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.18M | +16.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.40M | +25.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.25M | -15.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.12M | -26.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.02M | +85.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.12M | +48.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.47M | +77.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.51M | -9.7% |
| Q3 FY2023 | Sep 30, 2023 | $548.52K | -59.8% |
| Q2 FY2023 | Jun 30, 2023 | $754.95K | -49.9% |
| Q1 FY2023 | Mar 31, 2023 | $829.04K | – |
| Q4 FY2022 | Dec 31, 2022 | $1.67M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.36M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.51M | – |
See a number that looks wrong?